Entrada Therapeutics
Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.
$7.00
After-hours close+0.02 (+0.29%)
At close$6.98(−3.99%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.98 | — | — |
| Aug 2026 | −$0.97 | −$1.01 | −3.7% |
| May 2026 | −$1.06 | −$0.95 | +10.4% |
| Feb 2026 | −$1.32 | −$0.94 | +28.8% |
| Nov 2025 | −$1.04 | −$1.06 | −1.9% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Nov 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.98 | — | — | $2.1M | — | — |
| Aug 5, 2026 | −$0.97 | −$1.01 | −3.7% | $2.3M | $898.0K | −61.4% |
| May 7, 2026 | −$1.06 | −$0.95 | +10.4% | $2.9M | $875.0K | −70.0% |
| Feb 26, 2026 | −$1.32 | −$0.94 | +28.8% | $7.4M | $1.3M | −82.5% |
| Nov 6, 2025 | −$1.04 | −$1.06 | −1.9% | $8.5M | $1.6M | −81.0% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 5, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 7, 2024 | ||||||
| Mar 13, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 6, 2023 | ||||||
| Nov 7, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 15, 2022 | ||||||
| Dec 9, 2021 | ||||||
| Nov 1, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||